Consideration of Multiple Chronic Diseases in Randomized Controlled Trials
Authors:
- Alejandro R. JadadAJAlejandro R. Jadad
- Matthew J. ToMTMatthew J. To
- Mohamed EmaraMEMohamed Emara
- Jennifer JonesJJJennifer Jones
Open Access
- 28 December 2011
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 306 (24) , 2670-2672
Abstract
To the Editor: Before approval of a new drug, the US Food and Drug Administration (FDA) requires phase 3 clinical trials demonstrating efficacy. Usually trials are conducted in homogeneous populations and rarely include individuals with multiple chronic conditions. In the United States, more than 50% of people with chronic conditions have 2 or more diseases.1 Twenty-eight percent of the population lives with multiple chronic conditions, including 2 of 3 older individuals.2 Multiple chronic conditions account for 66% of the country's overall health expenditures2 and more than 95% of Medicare expenditures.3Keywords
This publication has 3 references indexed in Scilit:
- Managing Multiple Chronic Conditions: A Strategic Framework for Improving Health Outcomes and Quality of LifePublic Health Reports®, 2011
- Eligibility Criteria of Randomized Controlled Trials Published in High-Impact General Medical Journals: A Systematic Sampling ReviewYearbook of Dermatology and Dermatologic Surgery, 2008
- Managing Complexity in Chronic Care: An overview of the VA State-of-the-Art (SOTA) ConferenceJournal of General Internal Medicine, 2007